Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000086

Drug Information
NameCI-1033
SynonymsS1019_Selleck; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; Canertinib HCl; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; CI-1033; UNII-C78W1K5ASF; D03350; AC1L4G5R; I14-8433; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride; EC-000.2258; 267243-28-7; CI1033; PD-0183805; 289499-45-2; CHEMBL545315; PD 183805; CHEMBL31965; CID156413; CHEBI:61399; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; LS-185636; Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; Canertinib, PD-183805, CI1033, PD183805; AKOS005145818; Canertinib dihydrochloride [USAN]; Canertinib; CID156414; AC-2414; I06-1255; CI 1033; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; Canertinib dihydrochloride (USAN); AB1004832; Canertinib dihydrochloride; PD-183805; AC1L4G5O; UNII-ICJ93X8X90; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride
CompanyPfizer
IndicationCancer, NSCLC; cancer, colorectal; cancer, head and neck; cancer, thyroid; cancer, breast; cancer, mesothelioma; cancer, sarcoma, general; cancer, melanoma
[ICD9: 140-229, 162, 163, 172   ICD10: C00-C96, C33, C34, C43, C45]
Discontinued in Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C24H25ClFN5O3.2ClH/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6
-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16;;/
h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29);2*1H
InChIKeyJZZFDCXSFTVOJY-UHFFFAOYSA-N
Canonical SMILESC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl.Cl    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 289499-45-2
PubChem Compound IDCID 156413.
PubChem Substance IDSID 733824.
ClinicalTrials.govNCT00051051;
TargetAKTInhibitor[1]
AKTMultitarget[1]
Epidermal growth factor receptorInhibitor[1]
Epidermal growth factor receptorMultitarget[1]
Erbb2Inhibitor[1]
Erbb2Multitarget[1]
Receptor tyrosine-protein kinase erbB-4Inhibitor[1][2]
Receptor tyrosine-protein kinase erbB-4Multitarget[1][2]
Ref 1A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 2A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4274-82. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543